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Objectives. To evaluate lipid proﬁle changes after anti-TNF therapy in patients with psoriatic arthritis (PsA). Methods. Fifteen
PsA patients (eight polyarticular, four oligoarticular, two axial, and one mutilating) under inﬂiximab were included. None had
dyslipoproteinemiaorpreviousstatinuse.Totalcholesterol(TC)anditsfractions,inﬂammatorymarkers,andprednisoneusewere
evaluated. Results. The comparisonsoflipid levels between baseline and after three months (3M)of anti-TNF therapy showed that
there was a signiﬁcant increase in mean triglycerides (117.8±49.7versus 140.1±64.1mg/dL,P = 0.028)and VLDL-c (23.6±10.5
versus 28.4 ± 13.7mg/dL,P = 0.019) levels. In contrast, there were no diﬀerences in the mean TC (P = 0.28), LDL-c (P = 0.42),
and HDL-c (P = 0.26) levels. Analysis of the frequencies of each lipid alteration at baseline and at 3M were alike (P>0.05).
Positive correlations were found between VLDL-c and CRP (r = 0.647, P = 0.009) and between triglycerides and CRP (r = 0.604,
P = 0.017) levels at 3M. ESR reduction was observed after 3M (P = 0.04). Mean prednisone dose remained stable at beginning
and at 3M (P = 0.37). Conclusion. This study demonstrated that anti-TNF may increase TG and VLDL-c levels in PsA patients
after three months.
1.Introduction
Psoriatic arthritis (PsA) is a serious chronic inﬂammatory
arthropathy of unknown cause that is associated with cuta-
neous psoriatic lesions [1]. It is a chronic illness that occurs
in 6–39% of patients with psoriasis [2–5], depending of the
number of participants. It is calculated that 5 to 7% of the
patients with psoriasis will develop peripheral arthritis, and
the clinical forms distinguished are oligoarticular, polyartic-
ular, axial, and mutilating [1].
The treatment of PsA is conducted through the use of
nonhormonal anti-inﬂammatory (NSAID) agents that are
utilized in routine treatment and provide evident improve-
ments in joint pain [6]. Like corticosteroids, prednisone in
lowdosescaneventuallybeusedincasesofpersistentperiph-
eral arthritis [7]. In cases where patients are nonresponsive
to NSAID, the drug of ﬁrst choice is methotrexate, in weekly
doses (orally or intramuscularly), until control of the disease
is obtained [8]. A new era in the treatment of rheumatic
diseases began with the development of TNF-α-inhibitors,
where TNF-α is a cytokine that performs an important
role in inﬂammatory diseases, which have shown satisfac-
tory results for both joint and skin diseases [9, 10]. Adverse
eﬀects, including infections and lipid proﬁle changes, have
been related to this treatment for rheumatoid arthritis and
ankylosing spondylitis [11, 12]. However, there are only case
reports and one prospective study that evaluated the eﬀects
of these new medications on the lipid proﬁles of individuals2 Clinical and Developmental Immunology
with PsA, with very few patients and diﬀerent periods of
followup [13, 14].
Due to the paucity of studies, as well as the contradictory
r e s u l t si np r evi o u sﬁ n d i n g s ,t h ea i mo ft h i ss t u d yw a st oev a l -
uate lipid proﬁle changes pre- and post-anti-TNF therapy
treatment of PsA patients.
2.MaterialandMethods
2.1. Patients. This prospective study included 15 patients
presenting with PsA (Moll and Wright classiﬁcation [15]):
eight patients with polyarticular, four with oligoarticular,
two with axial, and one with mutilating forms of the disease,
who were treated with anti-TNF therapy (etanercept and
inﬂiximab) and assessed during follow-up appointments at
the High Cost Medication Dispensation Center (CEDMAC)
of the Hospital das Cl´ ınicas da Faculdade de Medicina da
Universidade de S˜ ao Paulo. Clinical and demographic data
were collected through review of the electronic charts and
medical consultations before the beginning of anti-TNF
treatment and after three months of treatment.
Theexclusioncriteriaincluded:previousdiagnosesofdy-
slipidemia, diabetes mellitus, renal failure, liver disease, and
useofmedicationsthatcouldinterfere with lipidmetabolism
(statins, ﬁbrates, and thiazide). A venous blood sample was
collected at fast for laboratory analysis before and after three
months of anti-TNF treatment.
This study was approved by the Research Ethic Commit-
tee of our University Hospital and an informed consent form
was obtained from all participants.
2.2. Lipid Proﬁle. Total cholesterol (TC) and triglycerides
(TGs) in the serum samples were measured enzymati-
cally (Boehinger-Mannhim, Argentina and Merck,Germany,
resp.) with an RA 1000 Analyzer (Technicon Instruments
Corp) [16, 17]. The high-density lipoprotein cholesterol
(HDL-c) levels were obtained after precipitation of the
very-low-density lipoprotein cholesterol (VLDL-c) from the
serum and from the low-density lipoprotein cholesterol
(LDL-c) using phosphotungstic acid and magnesium chlo-
rate [18]. VLDL-c and LDL-c levels were estimated since
all the samples had triglyceride levels lower than 400mg/dL
[17]. The VDL-c levels were determined using the ratio of
the triglyceride levels/ﬁve (TG/5), and the LDL-c levels were
estimated using the following equation [18]: TC = HDL-c +
TG/5 + LDL-c.
2.3. Inﬂammatory Activity Tests. The C-reactive protein dos-
age (CRP) (Roche Diagnosis, Indianapolis, USA) was asses-
sed by nephelometry. The erythrocyte sedimentation rate
(ESR) was obtained using the modiﬁed Westergreen tech-
nique.
2.4. Statistical Analysis. The results were presented in either
means and standard deviations or percentages. Statistical
analysis was performed using the GraphPad InStat version
2.00programandMicrosoftExcel,andStudent’st-testtoand
the Fisher’s exact test were used to compare the continuous
Table 1: Inﬂammatory markers, prednisone use/dose, and levels at
baseline and at three months after starting anti-TNF therapy.
Variable Baseline Three months P value
ESR (mean ± SD, mm in
the ﬁrst hour) 25.4 ± 22.4 12.8 ± 18.5 0.038
CRP (mean ± SD, mg/L) 17.6 ± 18.4 10.8 ± 15.9 0.058
Prednisone use, n (%) 7 (44) 7 (44) 1.0
Prednisone dose (mean ±
SD, mg/day) 2.0 ± 2.5 2.8 ± 5.2 0.24
TNF: tumor necrosis factor, ESR: erythrocyte sedimentation rate, and CRP:
C-reactive protein.
and categorical results, respectively. In all the statistical tests,
the level of signiﬁcance was set at 5% (P<0.05).
3.Results
From a total of 26 PsA patients, 11 were excluded due to
previous history of dyslipidemia or drugs use that interfere
with lipidlevelsand onedueto etanerceptuse. The mean age
o ft h e1 5p a t i e n t si n c l u d e di nt h i ss t u d yw a s4 1 . 9± 9.3 years,
and 53% were male and 93% were Caucasians. The average
duration of the disease was 14.6 ± 7.9 years. The patients
included in this study were using either inﬂiximab (n = 15)
or etanercept (n = 1).
Twelve (80%) patients experienced improvement in skin
and/or arthritis at 3 months. Analysis of inﬂammatory
markers revealed that there was a signiﬁcant reduction in
ESR values between preadministration of anti-TNF and after
three months (25.4 ± 22.4 versus 12.8 ± 18.5mm/1st hour,
P = 0.038). A trend to lower CRP was observed in these
two moments (17.6 ± 18.4 versus 10.8 ± 15.9mm/1st hour,
P = 0.058). Regarding prednisone use, the dose was low and
stable throughout the study, with a variation in the mean of
equivalentdosesbetweenthebeginningofthestudyandafter
three months (P = 0.24) (Table 1).
The total cholesterol (P = 0.30), LDL-c (P = 0.39) and
HDL-c (P = 0.26) levels did not showed signiﬁcant diﬀer-
ences in comparison to the values at the baseline and at three
months after treatment, respectively. In relation to the TG
levels (126.1 ± 50.1 versus 146.5 ± 61.4mg/dL, P = 0.024)
and VLDL-c levels (25.3 ± 10.6 versus 29.7 ± 12.5mg/dL,
P = 0.016), there was a signiﬁcant increase in the levels of
these lipids. The frequencies of dyslipidemia at baseline and
afterthreemonths werealike(P> 0.05)(Table 2).TC/HDL-
c ratio did not diﬀer in the two studied periods. Reinforcing,
positive correlations were found between VLDL-c and CRP
levels(r = 0.647,P = 0.009),as well as betweenTG and CRP
levels (r = 0.604, P = 0.017) at 3 months.
Glucose levels did not alter signiﬁcantly in the period
studied (88.2 ± 18.3 versus 90.6 ± 20.9mg/dL, P = 0.32).
4.Discussion
This study demonstrated a signiﬁcant increase in the triglyc-
eride and VLDL levels after three months of anti-TNF ther-
apy used in patients with PsA. Advantages of the presentClinical and Developmental Immunology 3
Table 2: Lipid proﬁle at baseline and at three months after starting
anti-TNF therapy in psoriatic arthritis patients.
Variable Baseline Three months P value
Total cholesterol (mg/dL) 157.1 ± 32.9 163.9 ± 33.8 0.30
HDL-c (mg/dL) 49.7 ± 15.4 45.1 ± 11.0 0.26
LDL-c (mg/dL) 91.7 ± 24.4 92.7 ± 18.9 0.39
VLDL-c (mg/dL) 25.3 ± 10.6 29.7 ± 12.5 0.016
Triglycerides (mg/dL) 126.1 ± 50.1 146.5 ± 61.4 0.024
Total cholesterol
>200mg/dL 1( 6 ) 0 1 . 0
HDL-c <40mg/dL(male)/
<50mg/dL(female) 5 (37) 5 (31) 1.0
LDL-c > 130mg/dL 0 0 1.0
VLDL-c > 40mg/dL 1 (6) 2 (12) 1.0
Triglycerides > 150mg/dL 5 (31) 8 (50) 0.47
TNF: tumor necrosis factor, HDL-: high-density cholesterol, LDL: low-
density cholesterol, and VLDL-c: very-low-density cholesterol.
study were to exclude patients with previous diagnoses of
dyslipidemia, diabetes mellitus, and use of statins and to
include only patients with established diagnosis of PsA.
As observed in our study, the TG and VLDL-c levels
increased signiﬁcantly. The TC, HDL-c, LDL-c, and CRP
levels did not have signiﬁcant variations during anti-TNF
treatment. Asigniﬁcant reductioninESRlevelswasobserved
when comparing the pre- and postperiods of anti-TNF
treatment, indicating a good response to TNF blockers. In
another study, Cauza et al. observed a signiﬁcant increase
in the TG levels and a decrease in HDL-c concentrations
in eight patients with PsA after inﬂiximab therapy [13].
Conversely, Sparnakis et al. found a signiﬁcant increase in
HDL-c levels during the evaluation and only a signiﬁcant
increase in TC in the ﬁrst month of evaluation. There was
a signiﬁcant ESR and CRP reduction only in the third
and ﬁrst month after inﬂiximab infusions in ten patients
with PsA [14] .T h er e m a r k a b l ea s s o c i a t i o no fV L D L - ca n d
CRP levels as well as between TG and CRP demonstrated
herein reinforces the role of inﬂammation and disease
activity in Takayasu patients. Indeed, CRP is a pentraxin
synthesized mainly in the liver in response to mediators of
inﬂammation, and there issubstantial evidencethat CRPbe-
sides has a strong predictive power for cardiovascular events
[19].
Similar studies with rheumatoid arthritis (RA) patients
also presented contradictory results. In a study by Popa
et al., they sought to evaluate whether anti-TNF treatment
modiﬁed the cardiovascular risk in 33 patients with RA.
They assessed the lipid proﬁles of patients before and at
two weeks after the ﬁrst adalimumab dose. They stated
that the treatment reduced inﬂammation and improved the
cardiovascular proﬁle of these patients by improving their
lipid proﬁles (HDL-c increase and LDL-c decrease) [11].
Another study evaluated34 patients with RA,using the three
TNF blockers, and found an increasing of TC, HDL-c, and
LDL-clevels,with no changesin TG levelsortheatherogenic
index after approximately six months of anti-TNF treatment
[20]. Soubrier et al. investigated the lipid proﬁles of 29 RA
patients before and after anti-TNF treatment for 14 weeks
and did not show any lipid proﬁle change in these patients
[21].
In a more recent study, Popa et al. investigated the eﬀects
of anti-TNF treatment on the lipid proﬁles of 55 RA patients
after one year of treatment. They could demonstrate that
the treatment modiﬁed the plasma concentrations in the
lipoproteinsofthese patients. There was an increase in HDL-
c concentrations and no changes in the atherogenic index
during the ﬁrst two weeks of treatment. Nevertheless, the
beneﬁcial eﬀects were not sustained over time; there were
eventually TC and LDL-c increases even though the HDL-
c levels did not change for twelve months. This ﬁnding
suggested a worsening of the lipid proﬁles and an increase in
the atherogenic index of these patients, which could increase
their cardiovascular risk [22].
TNF-α promotes expression of adhesion molecules in
endothelial cells, which initiates an inﬂammatory cascade in
the vessel wall [23, 24]. Additionally, TNF-α directly inter-
feres with the metabolic routes of TGs and cholesterol [25,
26]. TNF-α administration results in an elevation of TG
levels and a reduction of HDL-c levels [27].
Hypertriglyceridemia is a well-known factor of cardio-
vascular risk: high TG levels predict the subsequent occur-
rence of coronary artery disease [28]. The implementation
of strategies for control of hypertriglyceridemia, as well as
LDL-c levels, reduces coronary artery disease risk [29]. In
fact, patients with PsA present an increased prevalence of
atherosclerotic disease, sometimes subclinical [30]. Cardio-
vascular disease and its risk factors, including dyslipidemia,
are more common among patients with PsA than in control
groups [31].
It is clinically evident that PsA patients without cardio-
vascular risk factors or cardiovascular disease have an ele-
vated prevalence for macrovascular disease, which is repre-
sented by an increased carotid intima-media thickness [32].
This thickness independently correlates with activity param-
eters in PsA and traditional risk factors for atherosclerosis
[33]. These data corroborate the idea that special attention
and strict control of the risk factors for atherosclerotic
diseases in patients with PsA are necessary [30].
In summary, this study was able to demonstrate that
patients with PsA who received anti-TNF therapy showed
increased TG and VLDL levels after a three-month period.
Larger prospective long-term studies are necessary in order
to assess the impact of these lipid alterations in the cardio-
vascular disease in that group of patients.
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